en · de · es · pt
hplc-notes.peptides9002.com › News › Peptide Structure And Receptor Pharmacology — Reference Sheet

Peptide Structure And Receptor Pharmacology — Reference Sheet

By Editorial Desk · published 2026-05-06 · last reviewed 2026-06-12 · News

Fatty diacid raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-06-12. Anything still debated is marked as such rather than presented as settled.

Peptide Structure and Receptor Pharmacology

Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.

The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.

Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.

Tirzepatide Pharmacology and Development History

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.

Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.

Tirzepatide at a glance

PropertyValueNotes
Molar massapproximately 4813 Dacalculated from the 39-residue sequence
Appearancewhite to off-white powdertypical of lyophilised peptide material
Solubility classfreely soluble in watermeasured value depends on salt form and pH
Plasma protein binding>99 percentlinked to the fatty diacid side chain
Classdual GIP and GLP-1 receptor agonistreceptor activity varies with the assay used

Analytical Methods, Stability and Verification

Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.

Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.

Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.

Related pages on this site

Tirzepatide 分子背景与靶点

在生理层面,GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素,进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路,使胰岛素分泌的葡萄糖依赖性增强,并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比,双靶点作用在血糖控制和体重变化上的效应幅度更大,但具体贡献比例仍在研究之中。

脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强,从而延长循环半衰期,支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征,减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用,属于既定的药代动力学策略。

该化合物的名称与结构由国际非专利名称体系统一维持,不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。

Handling, Storage, and Analytical Control

Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.

Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.

Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.

Molecular Basis and Receptor Pharmacology

At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.

An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.

Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.

Supporting material

Macrophages () are a type of white blood cell of the innate immune system that engulf and digest pathogens, such as cancer cells, microbes, cellular debris and foreign substances, which do not have proteins that are specific to healthy body cells on their surface. This self-protection method can be contrasted with that employed by natural killer cells. This process of engulfment and digestion is called phagocytosis; it acts to defend the host against infection and injury. Macrophages are found in essentially all tissues, where they patrol for potential pathogens by amoeboid movement. They take various forms (with various names) throughout the body (e.g., histiocytes, Kupffer cells, alveolar macrophages, microglia, and others), but all are part of the mononuclear phagocyte system. Besides phagocytosis, they play a critical role in nonspecific defense (innate immunity) and also help initiate specific defense mechanisms (adaptive immunity) by recruiting other immune cells such as lymphocytes. For example, they are important as antigen presenters to T cells. In humans, dysfunctional macrophages cause severe diseases such as chronic granulomatous disease that result in frequent infections. Beyond increasing inflammation and stimulating the immune system, macrophages also play an important anti-inflammatory role and can decrease immune reactions through the release of cytokines. Macrophages that encourage inflammation are called M1 macrophages, whereas those that decrease inflammation and encourage tissue repair are called M2 macrophages.

standing on one bent leg and looking around the room, full range of motion e.g. an overhead press weight training exercise, and isometric exercises e.g. maintaining a Pilates pose. There is a strong focus on ensuring that the correct posture of the body and movement form for the exercise is achieved in order that the position of the joints is optimised throughout. There is ongoing debate about the effect of lifting heavy weights on the joints with some researchers arguing that this weakens the joints in the long term, especially in regard to ranges of movement which involve extreme ranges of flexion or extension i.e. a deep squat. Conversely, there are also proponents who argue that it strengthens the joints. Due to the greater possibility for heavy weight training to alter the position and alignment of the joints, powerlifters and body builders perform exercises for the stabilising muscles in order to keep the joints optimally positioned and aligned in their sockets. For example, they strengthen the rotator cuff muscles in order that the top of the humerus remains centrated in the glenoid fossa. Improved joint conditioning can also be achieved via a conscious attempt to regulate them, through a sense of self-awareness, so that they are aligned and positioned more optimally both when static and during movement. The focus on achieving this as a part of everyday life is ordinarily incorporated into the greater ambition of achieving good posture.

The dharmachakra (Sanskrit: धर्मचक्र dharmacakra, Pali: dhammacakka) or wheel of dharma is a symbol used in the Dharmic religions. It has a widespread use in Buddhism. The dharmachakra is considered one of the ashtamangala (auspicious signs) in Hinduism and Buddhism. In some specific regional sites like in Odisha, dharmachakra imagery in Hindu temples has been linked to sites with an earlier Buddhist presence. The symbol also finds its usage in modern India, most notably at the centre of the flag of India. Outside India, the dharmachakra has also been used as a decoration in Southeast Asian statues and inscriptions, beginning with the earliest period of Buddhism in Southeast Asia. It remains a major symbol of the Buddhist religion today.

=== Historical uses === Realgar was used by firework manufacturers in white flame and star compositions and to produce yellow smoke in daytime fireworks. Realgar has been used to kill weeds, insects, and rodents, even though more effective arsenic-based anti-pest agents are available such as cacodylic acid, (CH3)2As(O)OH, an organoarsenic compound used as an herbicide. Realgar was also used by Ancient Greek apothecaries to make a medicine known as "bull's blood". The Greek physician Nicander described a death by "bull's blood", which matches the known effects of arsenic poisoning. Bull's blood is the poison that is said to have been used by Themistocles and Midas for suicide. The Chinese name for realgar is 雄黃 (Mandarin xiónghuáng), literally 'masculine yellow', as opposed to orpiment which is 'feminine yellow'. Realgar was, along with orpiment, traded in the Roman Empire and was used as a red paint pigment. Early occurrences of realgar as a red paint pigment are known for works of art from China, India, Central Asia, and Egypt. It was used in Venetian fine-art painting during the Renaissance era, though rarely elsewhere in Europe, a use which died out by the 18th century. It was also used as medicine. Other traditional uses include manufacturing lead shot, printing, and dyeing calico cloth. It was used to poison rats in medieval Spain and in 16th century England.

=== Cellular aging and autophagy === Pathological aging and metabolic diseases are often characterized by defective mitochondria, the accumulation of misfolded proteins, and cellular senescence. Senescent cells secrete a harmful mix of inflammatory molecules known as the senescence-associated secretory phenotype (SASP). Preclinical studies suggest semaglutide counteracts these processes by activating the AMPK and SIRT1 pathways, which are fundamental for cellular autophagy and mitophagy. By upregulating proteins like parkin and TFEB, semaglutide enhances the clearance of damaged organelles. Additionally, by blockading FOXO transcription factors and NF-κB, the drug modulates SASP and upregulates anti-apoptotic proteins (such as Bcl-2), potentially delaying tissue degeneration and offering anti-aging benefits.

Sources: en.wikipedia.org

Notes from published material

== P == PAS – Positron annihilation spectroscopy Photoacoustic spectroscopy PAT or PACT – Photoacoustic tomography or photoacoustic computed tomography PAX – Photoemission of adsorbed xenon PC or PCS – Photocurrent spectroscopy Phase contrast microscopy PhD – Photoelectron diffraction PD – Photodesorption PDEIS – Potentiodynamic electrochemical impedance spectroscopy PDS – Photothermal deflection spectroscopy PED – Photoelectron diffraction PEELS – parallel electron energy loss spectroscopy PEEM – Photoemission electron microscopy (or photoelectron emission microscopy) PES – Photoelectron spectroscopy PINEM – photon-induced near-field electron microscopy PIGE – Particle (or proton) induced gamma-ray spectroscopy, see nuclear reaction analysis PIXE – Particle (or proton) induced X-ray spectroscopy PL – Photoluminescence Porosimetry Powder diffraction PTMS – Photothermal microspectroscopy PTS – Photothermal spectroscopy

=== Radiation characteristics === Flurpiridaz (18F) has a halflife of 109.8 minutes and the main photons useful for imaging are those resulting from gamma decay through interaction of the positron with an electron.

=== Novo Nordisk Foundation === On March 1, 2021, Thomsen was appointed CEO of the Novo Nordisk Foundation, a philanthropic organization that funds research in health, life sciences, and sustainability.

The development of the APCI interface for LC–MS started with Horning and collaborators in the early 1973. However, its commercial application was introduced at the beginning of the 1990s after Henion and collaborators improved the LC–APCI–MS interface in 1986. The APCI ion source/ interface can be used to analyze small, neutral, relatively non-polar, and thermally stable molecules (such as steroids, lipids, and fat soluble vitamins). These compounds are not well ionized using ESI. In addition, APCI can also handle mobile phase streams containing buffering agents. The liquid from the LC system is pumped through a capillary and there is also nebulization at the tip, where a corona discharge takes place. First, the ionizing gas surrounding the interface and the mobile phase solvent are subject to chemical ionization at the ion source. Later, these ions react with the analyte and transfer their charge. The sample ions then pass through small orifice skimmers by means of ion-focusing lenses. Once inside the high vacuum region, the ions are subject to mass analysis. This interface can be operated in positive and negative charge modes and singly-charged ions are mainly produced. APCI ion source can also handle flow rates between 500 and 2000 μl/min and it can be directly connected to conventional 4.6 mm ID columns.

== Bibliography == Flory, Paul. (1953) Principles of Polymer Chemistry. Cornell University Press. ISBN 0-8014-0134-8. Flory, Paul. (1969) Statistical Mechanics of Chain Molecules. Interscience. ISBN 0-470-26495-0. Reissued 1989. ISBN 1-56990-019-1. Flory, Paul. (1985) Selected Works of Paul J. Flory. Stanford Univ Press. ISBN 0-8047-1277-8.

Sources: en.wikipedia.org

Frequently asked questions

Is tirzepatide a small molecule or a peptide?

It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.

Why is the dosing interval long?

The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.

Does it act equally at both receptors?

In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.

What receptors does tirzepatide target?

It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.

Network